Inhaled Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Post-Infectious Cough: A Single-Center Randomized Controlled Clinical Trial

NCT07103980•Shanghai Changzheng Hospital

Summary

This study is an exploratory clinical trial. It is intended to investigate the efficacy of mesenchymal stem cell-derived exosome nebulization in the treatment of postinfectious cough through a randomized controlled clinical study, with a view to providing better treatment options for patients with postinfectious cough, improving their quality of life, and providing reference data for the subsequent multi-center clinical trials.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients aged 18-60 years.
•2. Diagnosis of post-infectious cough, which is defined as: after the symptoms of acute respiratory infection have disappeared, chest radiographs are normal, irritating dry cough or cough with small amounts of mucoid phlegm occurs, cough persists for 3 to 8 weeks, and other causes of cough are ruled out.
•3. Baseline cough visual analog scale\>=60mm.

Exclusion Criteria

•1. patients with any other disease that causes coughing (eg, Upper airway cough syndrome, eosinophilic bronchitis, gastroesophageal reflux cough, bronchial asthma, chronic obstructive pulmonary disease and bronchiectasis).
•2. Patients with serious lung diseases (eg, lung cancer, tuberculosis or pulmonary fibrosis).
•3. Patients with serious comorbidities, (eg, cardiovascular, cerebrovascular, liver, kidney or hematopoietic system diseases or other serious primary diseases)
•4. Current or ex-smokers quitting smoking for less than 6 months.
•5. Patients with a body temperature ≥37.3℃.
•6. Patients with white blood cell count or neutrophil count is higher than the upper limit of normal.
•7. Patients with abnormal chest X-rays.
•8. Patients Suspected or confirmed history of alcohol or drug abuse or mental illness.
•9. Patients with pregnancy, lactation or planning pregnancy.

Locations (1)

Shanghai changzheng hospital

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

July 16, 2024

Primary Completion Date

July 30, 2025

Completion Date

December 30, 2025

Last Updated

August 5, 2025

Enrollment

ESTIMATED participants

Conditions

Post-Infectious Cough

Interventions

Mesenchymal stem cell derived exosome nebulization combined with compound methoxyphenamine capsule

DRUG

Normal saline nebulization combined with the compound methoxyphenamine capsule

DRUG

Contacts

Hao Tang

CONTACT

+8615231788498 tanghao_0921@126.com

Oral Corticosteroids for Post-infectious Cough in Adults

NCT04232449

Post-infectious Cough

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 5, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions